glp-1 obesity drug supply news today Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, and The Obesity Society GLP-1 Targeted Peptide Weight Loss

Description

Aronne (verffentlicht im Journal JAMA) beobachtete bei Probanden, die nach neun Monaten Tirzepatid absetzten, eine kontinuierliche Gewichtszunahme ber weitere 52 Wochen

A report from PricewaterhouseCoopers found that GLP-1 drugs drove a disproportionate share of the $50 billion hike in pharmacy spending in 2024 (up from a $20 billion increase in 2023)

The data suggest that such caution may be unnecessary

In the LEAD series of studies, clinical data demonstrated that treatment with liraglutide for 26 weeks can reduce SBP [4]

The introduction of highly efficacious and generally safe medications for obesity treatment, such as GLP-1RAs, has disrupted this framework, reframing obesity as a medical issue that can be treated pharmacologically